British CRO wins con­tract for Covid-19 chal­lenge virus; Dutch agency aims to slash Zol­gens­ma prices in half

Ef­forts are un­der­way to de­vel­op a new chal­lenge virus for SARS-CoV-2, and a British CRO is mak­ing its case.

Open Or­phan said Mon­day that its sub­sidiary hVI­VO signed a con­tract with Im­pe­r­i­al Col­lege Lon­don to man­u­fac­ture such a chal­lenge virus. The con­tract is worth £3 mil­lion and hVI­VO will de­vel­op the virus based on new emerg­ing Covid-19 vari­ants of con­cern. The com­pa­ny hopes to then use the virus in fu­ture chal­lenge stud­ies.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN